86 related articles for article (PubMed ID: 14022548)
1. Further observations on the site of action of amethopterin.
CONDIT PT; MEAD JA
Biochem Pharmacol; 1963 Jan; 12():94-6. PubMed ID: 14022548
[No Abstract] [Full Text] [Related]
2. Increase of urinary citrovorum factor activity in patients receiving methotrexate (amethopterin).
LI MC; NIXON WE; FREEMAN MV
Proc Soc Exp Biol Med; 1958 Jan; 97(1):29-32. PubMed ID: 13518171
[No Abstract] [Full Text] [Related]
3. Reversal of aminopterin and amethopterin toxicity by citrovorum factor.
SCHOENBACH EB; GREENSPAN EM; COLSKY J
J Am Med Assoc; 1950 Dec; 144(18):1558-60. PubMed ID: 14794378
[No Abstract] [Full Text] [Related]
4. Development of resistance to 4-amino n10-methyl pteroylglutamic acid (Amethopterin) by Leuconostoc citrovorum.
HUTCHISON DJ; BURCHENAL JH
Proc Soc Exp Biol Med; 1952 Jul; 80(3):516-8. PubMed ID: 14949104
[No Abstract] [Full Text] [Related]
5. Antimetabolite-metabolite cancer chemotherapy using continuous intra-arterial methotrexate with intermittent intramuscular citrovorum factor. Method of therapy.
DUFF JK; SULLIVAN RD; MILLER E; ULM AH; CLARKSON BD; CLIFFORD P
Cancer; 1961; 14():744-52. PubMed ID: 13724783
[No Abstract] [Full Text] [Related]
6. Continuous arterial infusion of methotrexate with intermittent, intramuscular citrovorum factor therapy in head and neck cancer.
SULLIVAN RD
Trans Pac Coast Otoophthalmol Soc Annu Meet; 1961; 42():29-42. PubMed ID: 13918329
[No Abstract] [Full Text] [Related]
7. The treatment of head and neck cancer with the continuous arterial infusion of methotrexate and the intermittent intramuscular administration of citrovorum factor.
SULLIVAN RD; DALY JF
Trans Am Laryngol Assoc; 1961; 82():54-72. PubMed ID: 13918323
[No Abstract] [Full Text] [Related]
8. Continuous intraarterial methotrexate with simultaneous, intermittent, intramuscular citrovorum factor herapy in carcinoma of the cervix.
SULLIVAN RD; WOOD AM; CLIFFORD P; DUFF JK; TRUSSEL R; NARY DK; BURCHENAL JH
Cancer Chemother Rep; 1960 Jul; 8():1-6. PubMed ID: 13835652
[No Abstract] [Full Text] [Related]
9. Antimetabolite-metabolite combination cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human cancer.
SULLIVAN RD; MILLER E; SIKES MP
Cancer; 1959; 12():1248-62. PubMed ID: 13835650
[No Abstract] [Full Text] [Related]
10. Effects of folinic acid on amethopterin-induced inhibition of the Ehrlich ascites carcinoma.
SARTORELLI AC; UPCHURCH HF; BOOTH BA
Cancer Res; 1962 Jan; 22():102-6. PubMed ID: 14497283
[No Abstract] [Full Text] [Related]
11. The inhibition of dehydrogenases by folic acid and several of its analogs.
VOGEL WH; SNYDER R; SCHULMAN MP
Biochem Biophys Res Commun; 1963 Jan; 10():97-101. PubMed ID: 13997658
[No Abstract] [Full Text] [Related]
12. [THE SIGNIFICANCE OF THE FOLIC ACID METABOLISM FOR THE NORMAL AND PATHOLOGICAL MATURATION OF BLOOD CELLS].
WILMANNS W; JAENICKE L
Klin Wochenschr; 1963 Nov; 41():1077-82. PubMed ID: 14109864
[No Abstract] [Full Text] [Related]
13. Cancer therapy by intra-arterial methotrexate infusion. Protection of mucous membranes by topically applied citrovorum factor with hyaluronidase.
STOVNER J; ENGSETH A; BRENNHOVD I
Cancer Chemother Rep; 1962 Aug; 21():147-8. PubMed ID: 13917570
[No Abstract] [Full Text] [Related]
14. [Clinical studies on the metabolism of folic acid and the citrovorum factor. III. Metabolism of folic acid following intravenous injection of PGA. Appendix: Some observations on the effect of aminopterin upon folic acid metabolism and on heat labile citrovorum factor].
ANDO H
Naika Hokan; 1961; 8():530-41. PubMed ID: 13683325
[No Abstract] [Full Text] [Related]
15. Detection and measurement of antagonism to folic acid.
COLLIER HO; GRIMSHAW JJ; HUSKINSON PL
Br J Pharmacol Chemother; 1957 Dec; 12(4):521-8. PubMed ID: 13489185
[TBL] [Abstract][Full Text] [Related]
16. Reversal of methotrexate toxicity in mice by 5-methyltetrahydrofolic acid.
Blair JA; Searle CE
Br J Cancer; 1970 Sep; 24(3):603-9. PubMed ID: 5312191
[TBL] [Abstract][Full Text] [Related]
17. [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].
Sauer H; Schalhorn A
Onkologie; 1980 Apr; 3(2):64-71. PubMed ID: 6994007
[TBL] [Abstract][Full Text] [Related]
18. CONVERSION OF FOLIC ACID DERIVATIVES TO THEIR CONJUGATED FORMS BY CELLS OF STREPTOCOCCUS FAECALIS.
WOOD RC; WISE MF
Tex Rep Biol Med; 1965; 23():512-29. PubMed ID: 14336934
[No Abstract] [Full Text] [Related]
19. Trans-stimulation effects of folic acid derivatives on methotrexate transport by rat renal organic anion transporter, OAT-K1.
Takeuchi A; Masuda S; Saito H; Hashimoto Y; Inui K
J Pharmacol Exp Ther; 2000 Jun; 293(3):1034-9. PubMed ID: 10869408
[TBL] [Abstract][Full Text] [Related]
20. Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin.
Merzel RL; Boutom SM; Chen J; Frey C; Shedden K; Marsh EN; Banaszak Holl MM
Nanoscale; 2017 Feb; 9(7):2603-2615. PubMed ID: 28155935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
